Lumacaftor

June 13, 2017June 13, 2017

Orkambi Improves Lung Function of Children with Cystic Fibrosis, Update of Trial Results Indicates

Cystic Fibrosis, News

Vertex Pharmaceuticals‘ Orkambi significantly improved the lung function of children with cystic fibrosis, compared with a placebo, according to updated Phase 3 clinical trial results. An update of another Phase 3 trial’s ... Read more

November 3, 2015November 24, 2015

CF Fertility Rates Research Personal for University of Alabama at Birmingham Investigator

Cystic Fibrosis, News

For Sigrid Ladores, Ph.D., a pediatric nurse practitioner and an Assistant Professor at the University of Alabama at Birmingham School of Nursing, investigating reproductive health concerns of adolescents and young ... Read more

May 21, 2015November 5, 2015

New Insights into the Defective Protein Linked to Cystic Fibrosis

Cystic Fibrosis, News

Researchers at the National Health Institute, Doutor Ricardo Jorge and the University of Lisboa in Portugal recently published in the journal Science Signaling new insights into the processing of the ... Read more

May 13, 2015November 5, 2015

Vertex’s New CF Drug Combo Receives Positive FDA Recommendation

Cystic Fibrosis, News

The U.S. Food and Drug Administration (FDA) has issued a positive evaluation of ORKAMBI (lumacaftor/ivacaftor) as a recommended treatment for cystic fibrosis (CF) patients 12 years and older with two copies of the F508del mutation ... Read more

April 14, 2015November 5, 2015

New CF Treatments Could Mean Sky-High Health Costs

Cystic Fibrosis, News

A recent research project by Prime Therapeutics LLC (Prime) found that new treatments targeting specific gene mutations that cause cystic fibrosis could drastically increase costs associated with treating the condition. These results were presented at the Academy of ... Read more

November 6, 2014November 5, 2015

Lumacaftor/Ivacaftor Drug Combo for CF Patients With Two Copies Of F508del Mutation Gains U.S., European Approval

Cystic Fibrosis, News

Vertex Pharmaceuticals Incorporated has announced its submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European ... Read more